In this issue:
CLDN18.2-specific CAR T-cell therapy in gastric/GOJ cancer
PRODIGE 51-FFCD-GASTFOX: first-line TFOX vs. FOLFOX in HER2– gastric/GOJ cancer
A multi-dimensional integrated model to predict anti-PD-1 treatment outcomes in BTC
A blood miRNA signature for early-stage gastric cancer detection
Necessity of case-mix adjustments in hospital comparisons of oesophageal/ gastric cancer surgery outcomes
TRAE trajectory & prognosis with neoadjuvant chemo-immunotherapy in oesophageal SCC
Expression of STAT3, STAT4, JAK2 in solid-type poorly differentiated gastric cancer
CLDN18.2 expression discordance in primary vs. metastatic gastric cancer lesions
Please login below to download this issue (PDF)